IQV News | Roxom Stocks

Invest Private Security

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Preferreds paying dividends in bitcoin.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Everything Roxom publishes, in one feed.

Product launches, listings, and company news.

Commentary and analysis from the Roxom team.

Research Reports

In-depth research on bitcoin capital markets.

Weekly market updates, delivered to your inbox.

Roxom in the news, and press resources.

Where to find us, online and in person.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IQ

Volume

118

Next Earnings

October 27th

Loading chart

IQ

IQVIQVIA Holdings Inc.

IQV

Pay with—

Available Balance0.00

IQ

Mkt Cap

$44.42B

Volume

121

Next Earnings

October 27th

Chart Financials Earnings News About Insider Filings

Rare Disease Contract Research Organization (CRO) Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share OutlookThe global rare disease CRO market is projected to grow from $2.07 billion in 2025 to $3.16 billion by 2030, with an 8.9% CAGR. Growth is driven by expanding gene and cell therapy pipelines, increasing orphan drug approvals, precision medicine adoption, and decentralized clinical trials. Key trends include AI integration, patient registries, and real-world evidence utilization.GlobeNewswire Inc. · Sep 21, 2026

IQVIA Stock Rises 60% in 6 Months: Here's What You Should KnowIQVIA (IQV) has surged 60.1% over six months, driven by 6% organic growth in Q2 2026, with R&DS bookings up 19.3% and a $34.2 billion backlog. The company's rapid AI adoption—294 agents deployed across 90 use cases with 19 of top 20 pharma companies adopting solutions—is strengthening its competitive position and supporting sustained growth.Zacks Investment Research · Sep 16, 2026

VEEV Raises FY27 Outlook as Vault CRM and AI Momentum Accelerate FastVeeva Systems raised its fiscal 2027 revenue guidance to $3.682-$3.687B (implying ~15% growth), driven by strong Vault CRM adoption with commitments from 12 of top 20 biopharma firms and 180+ live customers. The company's Falcon AI product has five early adopters, though execution remains a key near-term priority. While profitability is maintained with a 44% operating margin, newer initiatives like CRM migrations and AI monetization still require sustained execution.Zacks Investment Research · Sep 3, 2026

Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?TransMedics (TMDX) reported Q2 2026 earnings that missed estimates by 12%, with EPS down 52.2% year-over-year to $0.44. However, revenues grew 20.7% to $189.9 million, driven by strong service revenue growth of 28.6%. The company raised its 2026 revenue guidance but lowered adjusted operating margin expectations due to accelerated OCS Kidney investments. Analyst estimates have shifted downward by 31.5% since the earnings release, resulting in a Zacks Rank #5 (Strong Sell) rating.Zacks Investment Research · Sep 3, 2026

Medera Presents Late-Breaking Clinical Trial Data at ESC Congress 2026 Demonstrating Durable Improvement in HFpEF Cardiac Filling Pressures Following SRD-002 Gene TherapyMedera Inc. announced 12-month data from its MUSIC-HFpEF Phase 1/2a clinical trial showing that 80% of patients met the prespecified threshold for normalization of cardiac filling pressures, with approximately 30% reduction in peak exercise pulmonary capillary wedge pressure. The trial demonstrated a favorable safety profile with no treatment-related serious adverse events across all 10 treated patients. Results support advancement to a randomized Phase 2b trial for SRD-002, a single-dose intracoronary AAV1/SERCA2a gene therapy for heart failure with preserved ejection fraction.GlobeNewswire Inc. · Aug 31, 2026

[Latest] Global eClinical Solutions Market Size/Share Worth USD 42.55 Billion by 2035 at a 13.98% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)The global eClinical Solutions market is projected to grow from USD 11.50 billion in 2025 to USD 42.55 billion by 2035, at a CAGR of 13.98%. Growth is driven by increased demand for efficient clinical trials, rising chronic disease prevalence, adoption of AI and cloud computing technologies, and decentralized trial models. Key players include Oracle, Veeva Systems, IQVIA, Medidata Solutions, and IBM Watson Health.GlobeNewswire Inc. · Aug 5, 2026

An IQVIA CEO Sold $26.1 Million as Bookings Hit a Record $3.15 BillionIQVIA CEO Ari Bousbib sold approximately 106,000 shares worth $26.1 million through an exercise-and-sell of expiring stock appreciation rights. The sale follows a strong Q2 earnings report with record clinical bookings of $3.15 billion and 8.7% revenue growth. Bousbib maintains a substantial 1.4 million share position, indicating the sale was routine calendar management rather than a bearish signal.The Motley Fool · Aug 2, 2026

Global Clinical Trials Market to Reach $176.32 Billion by 2030 as AI and Decentralized Research Accelerate GrowthThe global clinical trials market is projected to grow from $127.16 billion in 2025 to $176.32 billion by 2030, with a CAGR of 6.8%. Growth is driven by AI-enabled trial design, decentralized and virtual trials, precision medicine, and real-world evidence studies. North America leads the market while Asia-Pacific is the fastest-growing region. Strategic consolidation continues with major acquisitions strengthening end-to-end capabilities.GlobeNewswire Inc. · Jul 15, 2026

Pharmacovigilance Automation Market Size to Reach USD 5.25 Billion by 2035 | SNS InsiderThe global Pharmacovigilance Automation Market is expected to grow at a CAGR of 6.50% from 2025 to 2035, driven by increasing AI adoption, stringent drug safety regulations, and rising adverse event reporting volumes. North America leads with 38.60% market share, while Europe shows the fastest growth at 18.9% CAGR. Software solutions dominate with 72.40% market share, and pharmaceutical companies account for 58.60% of end-user demand.GlobeNewswire Inc. · Jun 24, 2026

Global Decentralized Clinical Trials Market Size/Share Worth USD 38.3 Billion by 2035 at a 14.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)The global decentralized clinical trials market is projected to grow from USD 9.9 billion in 2025 to USD 38.3 billion by 2035, at a CAGR of 14.5%. Growth is driven by digital health technologies, remote patient engagement, and ecosystem expansion involving CROs and platform vendors. Oncology represents the largest therapeutic segment at 45% market share, while pharmaceutical and biotech sponsors lead end-user adoption at 55% market share. North America currently dominates, while Asia-Pacific shows the fastest growth.GlobeNewswire Inc. · Jun 22, 2026

to start trading

IQ

IQVIQVIA Holdings Inc.

IQV

Pay with—

Available Balance0.00

Your PositionYou don't own any IQV yet.

Related Tickers

Earnings